Astal Laboratories Ltd

Astal Laboratories Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 29 December 2025, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 12 January 2026, providing investors with the latest perspective on the company’s position.

Astal Laboratories Ltd has seen its investment rating downgraded from Hold to Sell, driven primarily by a deterioration in technical indicators despite robust financial performance and attractive valuation metrics. The latest assessment by MarketsMOJO reflects a nuanced view of the company’s quality, valuation, financial trend, and technical outlook as of 29 Dec 2025.

Astal Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 December 2025, providing investors with the most recent insights into its performance and outlook.

Astal Lab, a microcap player in the Trading & Distributors sector, has experienced a revision in its market evaluation reflecting recent shifts in its fundamental and technical outlook. This adjustment comes amid a backdrop of subdued stock performance and evolving financial indicators.

Astal Laboratories reported record net sales of Rs 37.52 crore for the quarter ending September 2025, with a profit after tax of Rs 7.41 crore for the nine-month period. However, the company faces challenges with negative operating cash flow of Rs -12.52 crore, raising concerns about liquidity and operational efficiency.

Astal Laboratories Ltd., a micro-cap trading and distribution company with a market capitalisation of ₹96.00 crores, has delivered a quarter of remarkable top-line expansion tempered by margin compression concerns. In Q2 FY26, the company posted net profit of ₹2.58 crores, marking a 23.44% sequential increase from Q1 FY26's ₹2.09 crores and a robust 29.00% year-on-year growth from ₹2.00 crores in Q2 FY25. However, the stock has retreated 7.03% over the past week, trading at ₹88.80 as investors digest the margin dynamics beneath the headline numbers.

Astal Laboratories, a microcap in the Trading & Distributors sector, has shown significant sales growth of 152.08% and EBIT growth of 72.67% over five years. Its financial metrics indicate manageable debt levels, but its return on capital employed and return on equity are relatively low, suggesting potential challenges ahead.

Astal Laboratories has recently adjusted its evaluation, reflecting changes in its stock's technical landscape. The company reported impressive annual growth in net sales and operating profit, maintaining positive results over six quarters. With a low debt-to-equity ratio and a solid return on capital employed, it remains competitive in the market.

Astal Laboratories has recently adjusted its evaluation, reflecting changes in the stock's technical landscape. The company boasts strong financial metrics, including a low Debt to Equity ratio and impressive growth in net sales and operating profit. However, it faces challenges in management efficiency, as indicated by its Return on Equity.

Astal Laboratories has recently experienced a score adjustment reflecting changes in its technical outlook. The company has shown strong performance with a year-to-date return of 24.69% and significant growth in net sales and operating profit. Its financial structure remains conservative, with a low debt-to-equity ratio.